IS7942A - Nýjar píperídínafleiður sem stillar flakkboðaviðtaka CCR5 - Google Patents
Nýjar píperídínafleiður sem stillar flakkboðaviðtaka CCR5Info
- Publication number
- IS7942A IS7942A IS7942A IS7942A IS7942A IS 7942 A IS7942 A IS 7942A IS 7942 A IS7942 A IS 7942A IS 7942 A IS7942 A IS 7942A IS 7942 A IS7942 A IS 7942A
- Authority
- IS
- Iceland
- Prior art keywords
- ccr5
- missile
- receptor
- adjust
- piperidine derivatives
- Prior art date
Links
- 102100035875 C-C chemokine receptor type 5 Human genes 0.000 title 1
- 101710149870 C-C chemokine receptor type 5 Proteins 0.000 title 1
- 150000003053 piperidines Chemical class 0.000 title 1
- 102000005962 receptors Human genes 0.000 title 1
- 108020003175 receptors Proteins 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
- C07D211/24—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by sulfur atoms to which a second hetero atom is attached
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/56—Nitrogen atoms
- C07D211/58—Nitrogen atoms attached in position 4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
- C07D211/96—Sulfur atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Virology (AREA)
- Pulmonology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Transplantation (AREA)
- Ophthalmology & Optometry (AREA)
- Pain & Pain Management (AREA)
- AIDS & HIV (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE0203821A SE0203821D0 (sv) | 2002-12-20 | 2002-12-20 | Chemical Compounds |
| SE0300499A SE0300499D0 (sv) | 2003-02-24 | 2003-02-24 | Chemical compounds |
| SE0301425A SE0301425D0 (sv) | 2003-05-15 | 2003-05-15 | Chemical compounds |
| PCT/SE2003/002008 WO2004056773A1 (en) | 2002-12-20 | 2003-12-18 | Novel piperidine derivatives as modulators of chemokine receptor ccr5 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IS7942A true IS7942A (is) | 2005-07-18 |
Family
ID=32685861
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IS7942A IS7942A (is) | 2002-12-20 | 2005-07-18 | Nýjar píperídínafleiður sem stillar flakkboðaviðtaka CCR5 |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US20060189650A1 (enExample) |
| EP (1) | EP1572650A1 (enExample) |
| JP (1) | JP2006514107A (enExample) |
| KR (1) | KR20050084424A (enExample) |
| AR (1) | AR042628A1 (enExample) |
| AU (1) | AU2003288856B2 (enExample) |
| BR (1) | BR0317459A (enExample) |
| CA (1) | CA2508624A1 (enExample) |
| CL (1) | CL2003002678A1 (enExample) |
| CO (1) | CO5570665A2 (enExample) |
| IS (1) | IS7942A (enExample) |
| MX (1) | MXPA05006381A (enExample) |
| NZ (1) | NZ540780A (enExample) |
| PL (1) | PL377768A1 (enExample) |
| TW (1) | TW200505856A (enExample) |
| UY (1) | UY28139A1 (enExample) |
| WO (1) | WO2004056773A1 (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE0103818D0 (sv) | 2001-11-15 | 2001-11-15 | Astrazeneca Ab | Chemical compounds |
| SE0301369D0 (sv) | 2003-05-09 | 2003-05-09 | Astrazeneca Ab | Chemical compounds |
| SE0302090D0 (sv) * | 2003-07-16 | 2003-07-16 | Astrazeneca Ab | Chemical compounds |
| ATE361911T1 (de) * | 2003-07-31 | 2007-06-15 | Astrazeneca Ab | Piperidinderivate als ccr5-rezeptormodulatoren |
| TW200610761A (en) * | 2004-04-23 | 2006-04-01 | Astrazeneca Ab | Chemical compounds |
| CN101001860A (zh) | 2004-06-09 | 2007-07-18 | 霍夫曼-拉罗奇有限公司 | 杂环抗病毒化合物 |
| SE0401657D0 (sv) * | 2004-06-24 | 2004-06-24 | Astrazeneca Ab | Chemical compounds |
| SE0401656D0 (sv) * | 2004-06-24 | 2004-06-24 | Astrazeneca Ab | Chemical compounds |
| US7665658B2 (en) | 2005-06-07 | 2010-02-23 | First Data Corporation | Dynamic aggregation of payment transactions |
| KR20080056220A (ko) | 2005-10-19 | 2008-06-20 | 에프. 호프만-라 로슈 아게 | 페닐-아세트아마이드 ｎｎｒｔ 저해제 |
| DE602007013573D1 (de) | 2006-08-16 | 2011-05-12 | Hoffmann La Roche | Nicht-nukleosidische reverse-transkriptase-hemmer |
| BRPI0717288A2 (pt) * | 2006-09-28 | 2013-10-15 | Arete Therapeutics Inc | Inibidores de epóxido hidrolase solúvel |
| RU2469032C2 (ru) | 2006-12-13 | 2012-12-10 | Ф.Хоффманн-Ля Рош Аг | Производные 2-(пиперидин-4-ил)-4-фенокси- или фениламинопиримидина в качестве ненуклеозидных ингибиторов обратной транскриптазы |
| WO2011079007A1 (en) | 2009-12-23 | 2011-06-30 | Ironwood Pharmaceuticals, Inc. | Crth2 modulators |
| WO2012009134A1 (en) | 2010-07-12 | 2012-01-19 | Ironwood Pharmaceuticals, Inc. | Crth2 modulators |
| US20130216552A1 (en) | 2010-07-12 | 2013-08-22 | Ironwood Pharmaceuticals, Inc. | Crth2 modulators |
| WO2018068296A1 (en) | 2016-10-14 | 2018-04-19 | Merck Sharp & Dohme Corp. | PIPERIDINE DERIVATIVES AS LIVER X RECEPTOR β AGONISTS, COMPOSITIONS, AND THEIR USE |
| US11629196B2 (en) | 2020-04-27 | 2023-04-18 | Incelldx, Inc. | Method of treating SARS-CoV-2-associated hypercytokinemia by administering a human monoclonal antibody (PRO-140) that inhibits CCR5/CCL5 binding interactions |
| CN113444065A (zh) * | 2021-06-29 | 2021-09-28 | 浙江得乐康食品股份有限公司 | 一种莽草酸磺化物及其制备方法 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IE912759A1 (en) * | 1990-08-06 | 1992-02-12 | Smith Kline French Lab | Compounds |
| IL125658A0 (en) * | 1997-08-18 | 1999-04-11 | Hoffmann La Roche | Ccr-3 receptor antagonists |
| EP1013276A1 (en) * | 1998-12-23 | 2000-06-28 | Pfizer Inc. | Aminoazacycloalkanes as CCR5 modulators |
| US6432981B1 (en) * | 1999-06-11 | 2002-08-13 | Merck & Co., Inc. | Cyclopentyl modulators of chemokine receptor activity |
| GB0011838D0 (en) * | 2000-05-17 | 2000-07-05 | Astrazeneca Ab | Chemical compounds |
| GB0013060D0 (en) * | 2000-05-31 | 2000-07-19 | Astrazeneca Ab | Chemical compounds |
| GB0108046D0 (en) * | 2001-03-30 | 2001-05-23 | Astrazeneca Ab | Chemical compounds |
| EP1467986A1 (en) * | 2002-01-17 | 2004-10-20 | Eli Lilly And Company | Aza-cyclic compounds as modulators of acetylcholine receptors |
-
2003
- 2003-12-17 AR ARP030104682A patent/AR042628A1/es not_active Application Discontinuation
- 2003-12-18 PL PL377768A patent/PL377768A1/pl not_active Application Discontinuation
- 2003-12-18 WO PCT/SE2003/002008 patent/WO2004056773A1/en not_active Ceased
- 2003-12-18 KR KR1020057011450A patent/KR20050084424A/ko not_active Withdrawn
- 2003-12-18 BR BR0317459-0A patent/BR0317459A/pt not_active IP Right Cessation
- 2003-12-18 US US10/539,859 patent/US20060189650A1/en not_active Abandoned
- 2003-12-18 CL CL200302678A patent/CL2003002678A1/es unknown
- 2003-12-18 MX MXPA05006381A patent/MXPA05006381A/es active IP Right Grant
- 2003-12-18 EP EP03781235A patent/EP1572650A1/en not_active Withdrawn
- 2003-12-18 NZ NZ540780A patent/NZ540780A/en unknown
- 2003-12-18 AU AU2003288856A patent/AU2003288856B2/en not_active Ceased
- 2003-12-18 CA CA002508624A patent/CA2508624A1/en not_active Abandoned
- 2003-12-18 JP JP2005502630A patent/JP2006514107A/ja active Pending
- 2003-12-19 TW TW092136170A patent/TW200505856A/zh unknown
- 2003-12-19 UY UY28139A patent/UY28139A1/es unknown
-
2005
- 2005-06-13 CO CO05057099A patent/CO5570665A2/es not_active Application Discontinuation
- 2005-07-18 IS IS7942A patent/IS7942A/is unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20050084424A (ko) | 2005-08-26 |
| TW200505856A (en) | 2005-02-16 |
| CL2003002678A1 (es) | 2005-04-22 |
| AU2003288856B2 (en) | 2006-11-16 |
| NZ540780A (en) | 2008-04-30 |
| AU2003288856A1 (en) | 2004-07-14 |
| WO2004056773A1 (en) | 2004-07-08 |
| MXPA05006381A (es) | 2005-08-29 |
| US20060189650A1 (en) | 2006-08-24 |
| CO5570665A2 (es) | 2005-10-31 |
| CA2508624A1 (en) | 2004-07-08 |
| AR042628A1 (es) | 2005-06-29 |
| EP1572650A1 (en) | 2005-09-14 |
| JP2006514107A (ja) | 2006-04-27 |
| BR0317459A (pt) | 2005-11-16 |
| UY28139A1 (es) | 2004-07-30 |
| PL377768A1 (pl) | 2006-02-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IS7453A (is) | Trópan afleiður sem CCR5 stillar | |
| IS8466A (is) | 3-Sýklóalkýlamínópýrrólidín afleiður sem stillar á flakkboða viðtaka | |
| IS7942A (is) | Nýjar píperídínafleiður sem stillar flakkboðaviðtaka CCR5 | |
| IS7697A (is) | Pýrimídýlsúlfónamíðafleiður sem miðlar flakkboðaviðtaka | |
| DK1553929T3 (da) | Sammensætning med kontrolleret frigivelse. | |
| NO20052739D0 (no) | CCR5-antagonister som medikamenter | |
| ZA200606974B (en) | Substituted 1,2,3,4-tetrahydrolsoquinoline derivatives | |
| AU2003241836A1 (en) | Lpa receptor antagonists | |
| IL189657A0 (en) | N-phenyl-2-pyrimidine-amine derivatives | |
| DE60328925D1 (de) | Jittergenerator | |
| ATE450506T1 (de) | Indol-3-schwefelderivate | |
| GB0219896D0 (en) | Dihydropyridine derivatives | |
| PL375220A1 (en) | Piperidine derivatives | |
| IS7094A (is) | Píperidínafleiður sem eru gagnlegar sem stillar áviðtakavirkni flakkboða | |
| ZA200709147B (en) | Pyrimidindione derivatives as prokineticin 2 receptor antagonists | |
| DE60324360D1 (de) | Zuführvorrichtung | |
| IL162765A0 (en) | Piperidine derivatives | |
| DE50302630D1 (de) | Verstellantrieb | |
| DE50307512D1 (de) | Höhenverstellvorrichtung | |
| ATE335729T1 (de) | 3h-chinazoline -4-on derivaten | |
| IS8291A (is) | Pýrról-2,5-tvíþíónafleiður sem lifrar X viðtakastillar | |
| NO20044188L (no) | Kontrollerte frigjoringsdoseformer | |
| ATE423771T1 (de) | Tetrahydrochinolinderivate | |
| FI20021743A0 (fi) | Ohjausjärjestely | |
| IS8278A (is) | Sýkóprópýl afleiður sem NK3 viðtaka mótlyf |